Results 201 to 210 of about 42,543 (244)
Some of the next articles are maybe not open access.

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.

Journal of Clinical Oncology, 1990
R. Steis   +9 more
semanticscholar   +1 more source

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen   +2 more
exaly  

Lymphokine-activated killer (LAK) cells

Cellular Immunology, 1991
Zuhair K. Ballas, Wendy Rasmussen
openaire   +1 more source

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Ca-A Cancer Journal for Clinicians, 2022
Elshad Hasanov   +2 more
exaly  

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

Journal of Clinical Oncology, 1992
John A Thompson   +8 more
semanticscholar   +1 more source

Lymphokine-activated killer cells: regulation of activity

1990
Abstract Interleukin-2 (IL-2) has been reported to play a major role in many types of immune responses. This lymphokine induces proliferation of T lymphocytes and cells mediating NK activity, as well as production of lFN-γ; it also results in the induction oflymphokine-activated killer (LAK) cells with cytotoxic activity against fresh ...
openaire   +1 more source

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Competitive sustained exercise in humans, lymphokine activated killer cell activity, and glutamine – an intervention study

European Journal of Applied Physiology and Occupational Physiology, 1998
T. Rohde   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy